PD-L2 Antibody / Programmed death ligand 2 / CD273

Flow cytometry: 1-2ug/million cells in 0.1ml

Optimal dilution of the antibody should be determined by the researcher.

Recognizes a protein of about 31kDa, which is identified as PD-L2 (same as PDCD1LG2). Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T cell proliferation, cytokine production, differentiation of effector T cells and the induction of Bcl-x, a promoter of T cell survival. Conversely, engagement of CTLA4 by B7-1 or B7-2 may inhibit proliferation and IL-2 production. PD-L2 does not bind CD28, cytotoxic T lymphocyte A4 or ICOS (inducible co-stimulator). The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the Pdcd-1-Pdcd-L system could provide unique negative signaling to help prevent autoimmune disease.

Purified

0.2 mg/ml with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide

A recombinant fragment of human PD-L2 protein within amino acids 27-220 was used as the immunogen for the PDL2 antibody.

This PDL2 antibody is available for research use only.

Protein G affinity chromatography

Human

Q9Q51